This article is more than 5 years old. Information may no longer be current.
Early treatment could potentially prevent moderate visual loss from myopic CNV
SAN DIEGO — Myopic choroidal neovascularization patients who underwent early treatment avoided moderate visual loss, showing a need for raised awareness about the disease, a study reported here.
"Early presentation and prompt treatment offer better outcomes, emphasizing the need to educate patients on symptoms," Colin S. Tan, MD, and Tock Han Lim, MD, said. "The age of the patient and lesion size are important factors affecting prognosis. Further studies are required on the potential effects of reduced-fluence PDT on reducing visual loss."
They found that younger age, reduced-fluence photodynamic therapy and small lesion size are novel factors that could affect visual outcomes in myopic CNV cases.
They presented their study results in a poster at the American Society of Cataract and Refractive Surgery meeting. Their interventional cases series examined 18 consecutive cases of myopic CNV in Singapore. Moderate visual loss was loss of three or more lines of best corrected visual acuity.
Patients treated early with reduced-fluence PDT had the best results, they found. They noted that the study employed off-label use of fluence PDT.
- Disclosure: No products or companies are mentioned that would require financial disclosure.